Lo mejor del Congreso ESC 2014 de Barcelona
Jueves, 04 de Septiembre de 2014
De 19h a 20:30h
http://esc2014.secardiologia.es
Lo mejor sobre Insuficiencia Cardiaca
Dr. Esteban López de Sá
Hospital Universitario La Paz, Madrid
https://twitter.com/elopezdesa
College Call Girls Vyasarpadi Whatsapp 7001305949 Independent Escort Service
Lo mejor sobre Insuficiencia Cardiaca
1. Lo mejor sobre Insuficiencia
Cardiaca
Dr. Esteban López de Sá
Unidad de Cuidados Agudos Cardiológicos.
Hospital Universitario La Paz. Madrid
2. Aspectos a tratar
• Diagnóstico
• Tratamiento no farmacológico
• Tratamiento farmacológico
3. Aspectos a tratar
• Diagnóstico
• Tratamiento no farmacológico
• Tratamiento farmacológico
4. A new wearable textile vest for
pulmonary congestion tracking in
acutely decompensated heart failure
patients: A pilot study
Cuba-Gyllensten I, Gastelurrutia P, Riistama J,
Zamora E, Llibre C, Caballero A, de Antonio M,
Aarts R, Lupon J, and Bayes-Genis A
6. Improvements during therapy
• Relative changes in BI tracked fluid loss from weight changes
(p<0.001) and CSS changes (p<0.001)
• Significant correlations between BI and LVEF (r=0.450, p=0.047)
and NT-proBNP levels (r=−0.41, p=0.038).
7. Aspectos a tratar
• Diagnóstico
• Tratamiento no farmacológico
• Tratamiento farmacológico
8. Study Of Dietary Intervention Under 100
MMOL in Heart Failure
SODIUM-HF: A pilot study
Eloisa Colin-Ramirez BSc PhD, Finlay McAlister MD MSc, Yinggan Zheng
MA MEd, Sangita Sharma PhD, Paul Armstrong MD, Justin A Ezekowitz
MBBCh MSc
University of Alberta
Division of Cardiology, Department of Medicine
9. Study hypothesis
• Patients with HF following a low-sodium diet will
have a reduction in BNP levels and improvement in
quality of life when compared to patients following a
moderate-sodium diet.
12. Autonomic Modulation Therapy
Vagal
96 Eligible Patients, Implanted
63 ON therapy 32 OFF therapy
Lost Paired Data (n=4)
Deceased (n=1)
Safety FU Only (n=2)
Lost to FU (n=1)
Lost Paired Data (n=4)
Deceased (n=2)
Safety FU Only (n=1)
No Echo Data (n=1)
59 Therapy
Patients with
paired data sets
28 Control
Patients with
paired data sets
Modified intention to treat analysis
1 Death
95 Randomized
Stimulation
14. 11
Screening, Enrollment and Follow-up
Screening
n=78
Randomization
n=60
Right-Sided
Implantation
n=29
Titration
n=29
Inc / Exc failure (n=12)
Withdrawal (n=4)
Brady arrest (n=1)
Sudden death (n=1)
Left-Sided
Implantation
n=31
Titration
n=30
3-month F/U
n=29
3-month F/U
n=28
Death 1
n=1
Death 2
n=2
6-month F/U
n=29
6-month F/U
n=28
ANTHEM-HF Study
ANTHEM-HF
1. Embolic stroke (implant-related)
2. HF death (unrelated) and sudden death (unrelated)
15. ANTHEM-HF Study 15
Primary Efficacy Endpoints
- 1 5 - 1 0 - 5 0 5 1 0
P o o l e d
L e f t
R i g h t
P o o l e d
L e f t
R i g h t
LVESV (mL) LVEF (%)
Mean
ANTHEM-HF
Pooled: n=57; Left: n=28; Right: n=29 95% Confidence Interval
16. Aspectos a tratar
• Diagnóstico
• Tratamiento no farmacológico
• Tratamiento farmacológico
17. Effect of ferric carboxymaltose on
functional capacity in patients
with heart failure and iron deficiency
(CONFIRM-HF)
Piotr Ponikowski, Dirk J. van Veldhuisen, Josep Comin-Colet
Georg Ertl, Michel Komajda, Viacheslav Mareev
Theresa McDonagh, Alexander Parkhomenko, Luigi Tavazzi
Victoria Levesque, Claudio Mori, Bernard Roubert Gerasimos
Filippatos, Frank Ruschitzka, Stefan D. Anker
for the CONFIRM-HF Investigators.
Sponsor: Vifor Pharma Ltd.
18. CONFIRM-HF
• Design: Multicentre, randomised (1:1), double-blind, placebo-controlled
• Main inclusion criteria:
NYHA class II / III, LVEF ≤45%
BNP > 100 pg/mL or NT-proBNP > 400 pg/mL
Iron deficiency: serum ferritin <100 ng/mL or 100-300 ng/mL if TSAT <20%
Hb < 15 g/dL
• Blinding:
Clinical staff: unblinded and blinded personnel
Patients: usage of curtains and black syringes for injections
Correction phase
FCM up to 2000mg
(2 x 500-1000mg i.v.)
Maintenance phase
FCM treatment continues
if ID is not corrected
(500mg i.v.)
W36
Ferric Carboxymaltose (FCM)
Placebo
Screening
D0
1° EP:
6MWT
W6 W12 W24
Ponikowski P et al. ESC Heart Fail J 2014, in press
19. FCM improved 6MWT at week 24
FCM vs placebo: 33 ± 11 m (least squares mean ± SE)
P=0.002
20
10
0
-10
-20
-30
Week 24
LSM change in 6MWT distance
from baseline (m)
FCM (N=150)
Placebo (N=151)
30
Primary endpoint:
change in 6-minutes walking test distance at Week 24
Eur Heart J first published online August 31, 2014
20. PARADIGM-HF
Natriuretic Peptide System Renin Angiotensin System
pro-BNP
Neprilysin
Vasodilation
blood pressure
sympathetic tone
aldosterone levels
Fibrosis
hypertrophy
Natriuresis/Diuresis
Inactive
fragments
NT-pro BNP
X
Angiotensinogen
(liver secretion)
Angiotensin II
AT1 receptor
X
Vasoconstriction
blood pressure
sympathetic tone
aldosterone
fibrosis
hypertrophy
Heart Failure
O
NH
N
N
N
N
LCZ696
O
OH
O
OH HN O
HO O
Valsartan
AHU377
↓
LBQ657
BNP
Angiotensin I
LCZ696 A First-in-Class
Angiotensin Receptor
Neprilysin Inhibitor
21. PARADIGM-HF: Entry Criteria
• NYHA class II-IV heart failure
• LV ejection fraction ≤ 40% 35%
• BNP ≥ 150 (or NT-proBNP ≥ 600), but one-third lower
if hospitalized for heart failure within 12 months
• Any use of ACE inhibitor or ARB, but able to tolerate
stable dose equivalent to at least enalapril 10 mg daily
for at least 4 weeks
• Guideline-recommended use of beta-blockers and
mineralocorticoid receptor antagonists
• Systolic BP ≥ 95 mm Hg, eGFR ≥ 30 ml/min/1.73 m2
and serum K ≤ 5.4 mEq/L at randomization
23. PARADIGM-HF: Patient Disposition
10,521 patients screened at
1043 centers in 47 countries
Did not fulfill criteria
for randomization
(n=2079)
Randomized erroneously
or at sites closed due to
GCP violations (n=43)
8399 patients randomized for ITT analysis
LCZ696 (n=4187)
At last visit
375 mg daily
11 lost to follow-up
Enalapril (n=4212)
At last visit
18.9 mg daily
9 lost to follow-up
median 27 months
of follow-up
24. PARADIGM-HF: CV Death or HF
Hospitalization (Primary Endpoint)
40
32
24
16
8
0
Enalapril
(n=4212)
360 540 720 900 1080 1260
Days After Randomization
0 180
Patients at Risk
1117
Kaplan-Meier Estimate of
Cumulative Rates (%)
914
LCZ696
(n=4187)
HR = 0.80 (0.73-0.87)
P = 0.0000002
Number needed to treat = 21
LCZ696 4187 3922 3663 3018 2257 1544 896 249
Enalapril 4212 3883 3579 2922 2123 1488 853 236
25. PARADIGM-HF:
Effect of LCZ696 vs Enalapril on Primary
Endpoint and Its Components
LCZ696
(n=4187)
Enalapril
(n=4212)
HR
(95% CI)
P
Value
Primary
endpoint
914
(21.8%)
1117
(26.5%)
0.80
(0.73-0.87)
0.0000002
Cardiovascular
death
558
(13.3%)
693
(16.5%)
0.80
(0.71-0.89)
0.00004
Hospitalization
for heart failure
537
(12.8%)
658
(15.6%)
0.79
(0.71- 0.89)
0.00004
26. Angiotensin Neprilysin Inhibition With LCZ696
Doubles Effect on CV Death of Current
10%
Inhibitors of the RAS
20%
20%
30%
40%
ACE
inhibitor
Angiotensin
receptor
blocker
0%
% Decrease in Mortality
18%
Angiotensin
neprilysin
inhibition
15%